Equity Profile

GILD

Gilead Sciences, Inc.

Health CareBiotechnology$160.4B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Gilead Sciences, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases, particularly in the fields of HIV, liver diseases, and oncology....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and will help gauge how well Gilead is managing costs and generating revenue.

N/A

Revenue Growth

Revenue growth is vital for assessing the company's ability to expand its market presence and sustain operations, especially in a competitive biotech landscape.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

GILD Q2-2026 Earnings Preview

Context

Company Snapshot

Gilead Sciences, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases, particularly in the fields of HIV, liver diseases, and oncology. With a market cap of $160 billion, Gilead plays a crucial role in the healthcare sector, addressing significant medical needs through its research and product offerings.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+11.92%

Avg Stock Reaction

-0.05%

Last Quarter Recap

In Q1 2026, Gilead reported an EPS of $2.03, exceeding estimates by 7.69%. However, the stock declined by 1.64% the following day, indicating mixed investor sentiment despite the earnings beat.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Gilead's upcoming earnings report, especially given its consistent history of beating EPS estimates. However, the lack of specific revenue guidance raises concerns about future growth.

Bull Case

If Gilead continues its trend of beating EPS estimates and shows strong product sales, it could lead to a positive market reaction and renewed investor confidence.

Bear Case

Conversely, if Gilead fails to meet expectations or provides weak guidance, it could lead to a significant drop in stock price, reflecting investor disappointment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the revenue growth rate for Gilead's key product lines?

Revenue growth will be a critical indicator of the company's market performance and future prospects, especially in light of competitive pressures.

Will Gilead provide any guidance on future product launches or pipeline developments?

Insights into upcoming products and pipeline advancements could significantly influence investor sentiment and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may underestimate Gilead's potential for strong revenue growth driven by new product launches and increased market demand.

Supporting Evidence

Gilead has consistently beaten EPS estimates, indicating strong operational performance.

The options market is pricing in a larger move than historical averages, suggesting heightened expectations.

Insider selling may indicate caution, but it does not necessarily reflect the company's growth potential.

Key Risk

If Gilead's revenue growth exceeds 10%, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around Gilead's ability to sustain growth in a competitive biotech environment.

Bull Confirmed If

A revenue growth rate of over 10% compared to the previous quarter would confirm the bull case.

Bear Confirmed If

A revenue growth rate below 5% would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±3.77%

Historical Avg

±1.2%

Pricing rich

The options market is pricing in a move of approximately 3.77% in either direction, indicating uncertainty about the upcoming earnings report.

Options are pricing ±3.8% while GILD has averaged ±1.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

22.3%

Calls (429K)P/C Ratio: 0.42Puts (148K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 14 of 29 (48%)

This setup has occurred 30 times across Health Care in the last 2 years. 14 of 29 faded and 15 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.7%, with a raw directional average of +2.7% (modestly positive historical bias).

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$845,760.00

6,000 sh

2 insiders

Net

$845,760.00

Net selling

Most Active Insiders· 2 open-market trades

Chief Financial OfficerDickinson Andrew D
$422,880.00

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Gilead beats expectations and raises guidance, history suggests a potential stock increase of around 1.16%, confirming bullish sentiment.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may react moderately, reflecting uncertainty.

Miss

If Gilead misses expectations, history suggests a potential decline of around 1.16%, indicating investor disappointment.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-NJJosh GottheimerRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the performance of Gilead's key product lines.
2Any commentary on competitive pressures in the biotech sector.
3Details about upcoming product launches or pipeline developments.
4Insights into cost management and operational efficiency.
5Management's outlook on market trends and demand for Gilead's therapies.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Gilead Sciences, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases, particularly in the fields of HIV, liver diseases, and oncology....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and will help gauge how well Gilead is managing costs and generating revenue.

N/A

Revenue Growth

Revenue growth is vital for assessing the company's ability to expand its market presence and sustain operations, especially in a competitive biotech landscape.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

GILD Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+11.92%

Avg Stock Reaction

-0.05%

Last Quarter Recap

In Q1 2026, Gilead reported an EPS of $2.03, exceeding estimates by 7.69%. However, the stock declined by 1.64% the following day, indicating mixed investor sentiment despite the earnings beat.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Gilead continues its trend of beating EPS estimates and shows strong product sales, it could lead to a positive market reaction and renewed investor confidence.

Bear Case

Conversely, if Gilead fails to meet expectations or provides weak guidance, it could lead to a significant drop in stock price, reflecting investor disappointment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the revenue growth rate for Gilead's key product lines?

Revenue growth will be a critical indicator of the company's market performance and future prospects, especially in light of competitive pressures.

Will Gilead provide any guidance on future product launches or pipeline developments?

Insights into upcoming products and pipeline advancements could significantly influence investor sentiment and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may underestimate Gilead's potential for strong revenue growth driven by new product launches and increased market demand.

Supporting Evidence

Gilead has consistently beaten EPS estimates, indicating strong operational performance.

The options market is pricing in a larger move than historical averages, suggesting heightened expectations.

Insider selling may indicate caution, but it does not necessarily reflect the company's growth potential.

Key Risk

If Gilead's revenue growth exceeds 10%, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around Gilead's ability to sustain growth in a competitive biotech environment.

Bull Confirmed If

A revenue growth rate of over 10% compared to the previous quarter would confirm the bull case.

Bear Confirmed If

A revenue growth rate below 5% would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±3.77%

Historical Avg

±1.2%

Pricing rich

The options market is pricing in a move of approximately 3.77% in either direction, indicating uncertainty about the upcoming earnings report.

Options are pricing ±3.8% while GILD has averaged ±1.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

22.3%

Calls (429K)P/C Ratio: 0.42Puts (148K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 14 of 29 (48%)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$845,760.00

6,000 sh

2 insiders

Net

$845,760.00

Net selling

Most Active Insiders· 2 open-market trades

Chief Financial OfficerDickinson Andrew D
$422,880.00

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Gilead beats expectations and raises guidance, history suggests a potential stock increase of around 1.16%, confirming bullish sentiment.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may react moderately, reflecting uncertainty.

Miss

If Gilead misses expectations, history suggests a potential decline of around 1.16%, indicating investor disappointment.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-NJJosh GottheimerRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the performance of Gilead's key product lines.
2Any commentary on competitive pressures in the biotech sector.
3Details about upcoming product launches or pipeline developments.
4Insights into cost management and operational efficiency.
5Management's outlook on market trends and demand for Gilead's therapies.